

Regimen Reference Order – GENU – apalutamide

ARIA: GENU – [apalutamide]

Planned Course: Once daily until disease progression or unacceptable toxicity (1 cycle = 30 days)

Indication for Use: Prostate Cancer, Non-metastatic Castration-Resistant

OR

Prostate Cancer, Metastatic Castration-Sensitive

Proceed with treatment if:

ANC equal to or greater than $1 \times 10^9/L$ AND Platelets equal to or greater than $50 \times 10^9/L$

❖ **Contact Physician if parameters not met**

SEQUENCE OF MEDICATION ADMINISTRATION

Treatment Regimen – GENU – apalutamide

Drug	Dose	CCMB Administration Guideline
apalutamide	240 mg	Orally once daily with or without food Swallow whole (Self-administered at home)
apalutamide (ERLEADA®) available dosage strengths: 60 mg and 240 mg tablets Classification: Non-Cytotoxic, Hazardous		

REQUIRED MONITORING

Baseline

- CBC, serum creatinine, electrolytes, liver enzymes, glucose, TSH, testosterone and PSA as per Physician Orders
- Blood pressure
- EKG for patients on anti-arrhythmics at physician's discretion
- Bone density at physician's discretion

Month 2 and 3

- CBC, serum creatinine, electrolytes, liver enzymes, glucose, TSH, testosterone and PSA as per Physician Orders
- Blood pressure at each clinic visit

Subsequent clinic visits (every 3 months)

- CBC, serum creatinine, electrolytes, liver enzymes, glucose, TSH, testosterone and PSA as per Physician Orders
- Blood pressure at each clinic visit (patients can also monitor at home)

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
None required		

INSTRUCTIONS FOR PATIENT

- Inform patient to report rash or uncontrolled diarrhea
 - Prescriber should be notified of blood pressure measurements greater than 160/95 mmHg
 - apalutamide has potential for drug-drug interactions. Patients should notify clinic prior to starting any new medication
 - Avoid grapefruit and grapefruit juice, Seville oranges (i.e. orange marmalade) and starfruit
-

ADDITIONAL INFORMATION

- Androgen Deprivation Therapy (ADT) (e.g. goserelin, leuprolide, degarelix) is continued lifelong throughout treatment course/lines of systemic therapy for prostate cancer
- Patients are at increased fracture risk
- apalutamide can cause hypertension
- apalutamide can prolong QT interval
- apalutamide can cause hypothyroidism
- apalutamide has been associated with seizures